Enter your keyword

Efficiently Creating Value with Innovative Science

Press Releases

Date Title and Summary Additional Formats
Toggle Summary OXiGENE Provides Update on Vascular Targeting Programs in Ophthalmology
OXiGENE Provides Update on Vascular Targeting Programs in Ophthalmology WALTHAM, Mass.--(BUSINESS WIRE)--June 20, 2005--OXiGENE, Inc. (NASDAQ and XSSE: OXGN), a leading developer of biopharmaceutical compounds designed to target aberrant blood vessels within solid tumor cancers and ocular
View HTML
Toggle Summary OXiGENE to Present at Friedman Billings Ramsey Ninth Annual Growth Conference: June 1st at 11am
OXiGENE to Present at Friedman Billings Ramsey Ninth Annual Growth Conference: June 1st at 11am WALTHAM, Mass.--(BUSINESS WIRE)--May 27, 2005--OXiGENE, Inc. (NASDAQ: OXGN) (XSSE: OXGN), a leading developer of biopharmaceutical compounds designed to target aberrant blood vessels within solid tumor
View HTML
Toggle Summary OXiGENE Announces Positive Phase Ib Update of CA4P with Radiotherapy at ASCO
OXiGENE Announces Positive Phase Ib Update of CA4P with Radiotherapy at ASCO -CA4P well tolerated with radiotherapy for lung and prostate cancers, anti-tumor activity observed- WALTHAM, Mass.--(BUSINESS WIRE)--May 16, 2005--OXiGENE, Inc. (NASDAQ: OXGN, XSSE: OXGN) today announced that a clinical
View HTML
Toggle Summary OXiGENE Announces Presentation at ASCO of Positive Tumor Response Data in Phase Ib Trial of CA4P With Chemotherapy
OXiGENE Announces Presentation at ASCO of Positive Tumor Response Data in Phase Ib Trial of CA4P With Chemotherapy Clinical Investigator Reports that CA4P in Combination with Carboplatin and/or Paclitaxel Indicates Anti-tumor Activity and No Unexpected Toxicity WALTHAM, Mass.--(BUSINESS WIRE)--May
View HTML
Toggle Summary OXiGENE Reports First-Quarter 2005 Operational and Financial Results
OXiGENE Reports First-Quarter 2005 Operational and Financial Results WALTHAM, Mass.--(BUSINESS WIRE)--April 27, 2005--OXiGENE, Inc. (NASDAQ: OXGN) (XSSE: OXGN): Recent Accomplishments: Announced positive data supporting clinical programs of CA4P and OXi4503 at the recent AACR meeting Observed
View HTML
Toggle Summary OXiGENE Announces Positive New Preclinical Safety and Efficacy Data for CA4P at AACR
OXiGENE Announces Positive New Preclinical Safety and Efficacy Data for CA4P at AACR WALTHAM, Mass.--(BUSINESS WIRE)--April 19, 2005--OXiGENE, Inc. (NASDAQ: OXGN) (XSSE: OXGN): -CA4P in Combination Treatment Causes Complete Remissions in Anaplastic Thyroid Preclinical Model- -Safety Profile for
View HTML
Toggle Summary OXiGENE Announces New Preclinical Data Presented at AACR Supporting Development of Lead Vascular Targeting Agents; OXi4503 Shows Promising Preclinical Efficacy Data in Colorectal Tumors
OXiGENE Announces New Preclinical Data Presented at AACR Supporting Development of Lead Vascular Targeting Agents; OXi4503 Shows Promising Preclinical Efficacy Data in Colorectal Tumors CA4P's Safety Profile Further Characterized WALTHAM, Mass., Apr 18, 2005 (BUSINESS WIRE) -- OXiGENE, Inc.
View HTML
Toggle Summary OXiGENE to Webcast First-Quarter 2005 Financial Results Conference Call April 27; Live Webcast to be Available at www.oxigene.com
OXiGENE to Webcast First-Quarter 2005 Financial Results Conference Call April 27; Live Webcast to be Available at www.oxigene.com WALTHAM, Mass.--(BUSINESS WIRE)--April 15, 2005--OXiGENE, Inc. (NASDAQ: OXGN, XSSE: OXGN) invites the public to listen to a live audio webcast of the Company's
View HTML
Toggle Summary OXiGENE Announces Presentations on Lead Vascular Targeting Agents at American Association of Cancer Research
OXiGENE Announces Presentations on Lead Vascular Targeting Agents at American Association of Cancer Research Seven Poster Presentations on CA4P and OXi4503 at AACR WALTHAM, Mass.--(BUSINESS WIRE)--April 13, 2005--OXiGENE, Inc. (NASDAQ: OXGN, XSSE: OXGN) today announced the topics and schedules for
View HTML
Toggle Summary OXiGENE to Present at Lehman Brothers Eighth Annual Global HealthCare Conference: April 1st Presentation Available via Live Webcast
OXiGENE to Present at Lehman Brothers Eighth Annual Global HealthCare Conference: April 1st Presentation Available via Live Webcast WALTHAM, Mass.--(BUSINESS WIRE)--March 30, 2005--OXiGENE, Inc. (NASDAQ: OXGN) (XSSE: OXGN), a leading developer of biopharmaceutical compounds designed to target
View HTML